|
|
|
|
|
|
|
|
|
|
|
05.10.26 - 22:09
|
NeoGenomics Announces Executive Leadership and Board of Directors Succession Plan (Business Wire)
|
|
|
Warren Stone, current President and COO, to become CEO and a member of the Board effective January 4, 2027Tony Zook to remain CEO through January 3, 2027, and become Executive Chairman effective January 4, 2027Lynn Tetrault, current Chair and Board member since 2015, to step down as Chair effective January 4, 2027, continue to serve as an independent director until the 2027 Annual Meeting of Stockholders, and not stand for reelection at that meetingMichael Kelly to serve as Lead Independent Director effective January 4, 2027Preliminary unaudited third quarter revenue is expected to be approximately $209 million, with NGS revenue growth of approximately 28%. Full-year total revenue guidance expected to increase at midpoint, resulting from third-quarter performanceFORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that as part of a planned succession, ...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
28.07.26 - 22:09
|
NeoGenomics Reports Second Quarter 2026 Results (Business Wire)
|
|
|
Total revenue increased 11% YoY to $202 million
Clinical services revenue grew 14%, with NGS revenue growth of 26%
Company raises full-year 2026 revenue and adjusted EBITDA guidanceFORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO) (the “Company”), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its second-quarter results for the period ended June 30, 2026.
Financial Highlights
For the three-month period ended June 30, 2026, as compared to the same period in 2025:
Increased total revenue by 11% to $202 million
Increased clinical revenue by 14% to $187 million driven by robust NGS growth of 26%
Recorded GAAP net income of $2 million, including a gain on extinguishment of debt of $11 million
Delivered adjusted EBITDA(1) of $14 million, an increase of 36%
Generated $20 million from cash from operations to end the quarter with $146 million of cash, cash equivalents, and short-term investments
Business Highlights
Sharpened commerc...
|
|
|
|
|
07.07.26 - 13:06
|
NeoGenomics to Report Second Quarter 2026 Financial Results on July 28, 2026 (Business Wire)
|
|
|
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its second quarter 2026 financial results after the close of U.S. financial markets on Tuesday, July 28, 2026. Company management will host a webcast and conference call at 4:30 p.m. ET to discuss financial results and recent highlights.
The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com or by clicking here. The webcast will be archived and available for replay shortly after the conclusion of the call.
To access the live call via telephone, dial (888) 506-0062 (domestic) or (973) 528-0011 (international) at least five minutes prior to the call. The participant access code is 968605.
About NeoGenomics, Inc.
NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most compreh...
|
|
|
25.06.26 - 13:06
|
NeoGenomics Appoints Carolyn Starrett to its Board of Directors (Business Wire)
|
|
|
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of Carolyn Starrett to its Board of Directors.
Ms. Starrett brings over 25 years of commercial, product, and operations experience at data and technology companies, and a deep understanding of AI and data insights in cancer care and research. She spent the last ten years, from 2016 to 2026, at Flatiron Health, serving in a variety of executive roles and ultimately leading the company as CEO and Board Director from April 2021 to September 2025. She is currently the President of Starrett Advisory, an independent consulting and strategic advisory firm, working with clients on strategic topics at the intersection of healthcare delivery, drug development, data, and AI.
“We are very excited to welcome Carolyn to the NeoGenomics board,” said Lynn Tetrault, Chair of the Board of NeoGenomics. “Carolyn's experience using real-w...
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
